Cancer Hospital Chinese Academy Of Medical Science, Shenzhen Center

This phase 2 trial tests a combination of two drugs—becotatug vedotin (a targeted therapy) and pucotenlimab (an immunotherapy)—as a first treatment for advanced head and neck squamous cell carcinoma. It is for patients whose cancer has returned or spread and who cannot tolerate p…

This early-phase trial tests a personalized mRNA vaccine called RH125 in 36 people with advanced solid tumors who have no standard treatment options left. The vaccine is custom-made based on each patient's tumor mutations and is given alone or with a PD-1 blocker. The main goals …